Escalated Infliximab Dosing in Hidradenitis Suppurativa: A National Survey of Expert Practice
International Journal of Dermatology · 07.08.2026
DOI: 10.1111/ijd.70625 ↗Kurz gefasst
Leserbrief in der Zeitschrift International Journal of Dermatology, online erschienen am 07.08.2026. Verfasst von Adarsh Shidhaye und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, USA. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Medicine, NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, USA.
- Department of Dermatology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
ORCID-Profile: Adarsh Shidhaye, Nicole Edmonds, Gabrielle Schwartzman, Lindsey Buscemi, R Hal Flowers
Zitieren
APA
Shidhaye, A., Edmonds, N., Schwartzman, G., Buscemi, L., & Flowers, R. H. (2026). Escalated Infliximab Dosing in Hidradenitis Suppurativa: A National Survey of Expert Practice. International Journal of Dermatology. https://doi.org/10.1111/ijd.70625
Vancouver
Shidhaye A, Edmonds N, Schwartzman G, Buscemi L, Flowers RH. Escalated Infliximab Dosing in Hidradenitis Suppurativa: A National Survey of Expert Practice. International Journal of Dermatology. 2026. doi:10.1111/ijd.70625
BibTeX
@article{Shidhaye2026,
author = {Shidhaye, Adarsh and Edmonds, Nicole and Schwartzman, Gabrielle and Buscemi, Lindsey and Flowers, R Hal},
title = {Escalated Infliximab Dosing in Hidradenitis Suppurativa: A National Survey of Expert Practice},
journal = {International Journal of Dermatology},
year = {2026},
doi = {10.1111/ijd.70625}
}
EUVIMED